Oncotelic Therapeutics, Inc. (OTLC) Operating cash flow 2017–2025
Oncotelic Therapeutics, Inc. (OTLC) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$1.4MFY2025 · since FY2017: -$10.9M → -$1.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$1.4M | -86.8% |
| FY2024 | -$740,277 | +44.0% |
| FY2023 | -$1.3M | +9.1% |
| FY2022 | -$1.5M | +67.2% |
| FY2021 | -$4.4M | -57.7% |
| FY2020 | -$2.8M | -23.3% |
| FY2019 | -$2.3M | -846.4% |
| FY2018 | -$240,980 | +97.8% |
| FY2017 | -$10.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More OTLC financial trends
OTLC RevenueOTLC Net incomeOTLC Net marginOTLC Gross profitOTLC Gross marginOTLC Operating incomeOTLC Operating marginOTLC Free cash flowOTLC Capital expendituresOTLC Return on equityOTLC Stock buybacksOTLC Dividends paidOTLC Total assetsOTLC Total liabilitiesOTLC Shareholders’ equityOTLC overview →